Larimar Therapeutics Files 8-K

Ticker: LRMR · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1374690

Larimar Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyLarimar Therapeutics, Inc. (LRMR)
Form Type8-K
Filed DateDec 16, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, routine-filing

Related Tickers: LRMR

TL;DR

Larimar Therapeutics filed an 8-K, mostly routine stuff, no big news yet.

AI Summary

On December 16, 2024, Larimar Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events or financial updates detailed in the provided text. The company, formerly known as Zafgen, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This 8-K filing indicates a routine update or submission of documents to the SEC by Larimar Therapeutics, Inc., without disclosing specific new material information in the provided excerpt.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report with no disclosed material events, suggesting low immediate risk based on this information.

Key Numbers

  • 001-36510 — SEC File Number (Identifies the company's filing with the SEC.)
  • 20-3857670 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • Larimar Therapeutics, Inc. (company) — Registrant
  • ZAFGEN, INC. (company) — Former Company Name
  • December 16, 2024 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 2834 (sic_code) — Standard Industrial Classification

FAQ

What specific 'Other Events' are being reported by Larimar Therapeutics, Inc. in this 8-K filing?

The provided text for the 8-K filing does not detail the specific 'Other Events' being reported, only that this item is included.

What is the significance of the 'Financial Statements and Exhibits' being filed?

The filing indicates that financial statements and exhibits are being submitted, but the content of these documents is not described in the provided excerpt.

When was Larimar Therapeutics, Inc. formerly known as Zafgen, Inc.?

The filing states that the former company name was Zafgen, Inc., with a date of name change listed as March 1, 2010.

What is Larimar Therapeutics, Inc.'s primary business sector?

Larimar Therapeutics, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.

What is the principal executive office address for Larimar Therapeutics, Inc.?

The principal executive offices of Larimar Therapeutics, Inc. are located at Three Bala Plaza East, Suite 506, Bala Cynwyd, Pennsylvania, 19004.

Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-12-16 07:02:46

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share LRMR Nasdaq Global Market

Filing Documents

01 Other Events

Item 8.01 Other Events. Press Release On December 16, 2024, Larimar Therapeutics, Inc. (the " Company ") issued a press release announcing positive initial data from its ongoing long-term open label extension study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich's ataxia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Investor Presentation On December 16, 2024, the Company posted on its website an updated slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Below is a list of exhibits included with this Current Report on Form 8-K. Exhibit No. Document 99.1 Press Release issued by Larimar Therapeutics, Inc. on December 16, 2024* 99.2 Larimar Therapeutics, Inc. Corporate Presentation, dated December 16, 2024* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Larimar Therapeutics, Inc. Date: December 16, 2024 By: /s/ Carole S. Ben-Maimon, M.D. Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.